Paul Tudor Jones’s Lisata Therapeutics LSTA Stock Holding History

Paul Tudor Jones’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-183	Closed	-$16K	–	1595
2016 Q2	$16K	Hold	183	–	–	﹤0.01%	1574
2016 Q1	$21K	Hold	183	–	–	﹤0.01%	1681
2015 Q4	$30K	Hold	183	–	–	﹤0.01%	1596
2015 Q3	$41K	Hold	183	–	–	﹤0.01%	1483
2015 Q2	$51K	Buy	+183	New	+$68K	﹤0.01%	1442

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EGA

Eagle Global Advisors Houston, Texas $3.02B AUM 34.37% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Paul Tudor Jones's LSTA Position: Q3 2016 in Review

Paul Tudor Jones sold out of Lisata Therapeutics (LSTA) in Q3 2016, closing a stake of 183 shares — an estimated $16K sold.

Paul Tudor Jones first reported a position in LSTA in Q2 2015 and held it in 5 quarters. The position peaked at $51K in Q2 2015. 28 funds tracked by Wall St. Rank hold LSTA as of Q3 2016.

Paul Tudor Jones reported no remaining Lisata Therapeutics position as of Q3 2016 after selling out during the quarter.
Paul Tudor Jones sold 183 Lisata Therapeutics shares in Q3 2016, an estimated $16K.
Paul Tudor Jones first reported a position in Lisata Therapeutics in Q2 2015 and held it in 5 quarters.
Paul Tudor Jones's Lisata Therapeutics position peaked at $51K in Q2 2015.
28 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2016.

Based on Tudor Investment Corp's 13F filing for Q3 2016, filed 14 Nov 2016.